Financials

	2022	2023
Net sales	4.85Cr 4.24Cr 3.91Cr 3.6Cr 6.79Cr 466.7Cr 6.94Cr 47Cr 18Cr 228.57Cr 18Cr 18Cr 786.84Cr	4.92Cr 4.3Cr 3.96Cr 3.65Cr 6.89Cr 473.46Cr 7.04Cr 47Cr 19Cr 231.88Cr 18Cr 18Cr 798.24Cr
Net income	-2.86Cr -2.5Cr -2.31Cr -2.13Cr -4.01Cr -275.75Cr -4.1Cr -28Cr -11Cr -135.05Cr -11Cr -11Cr -464.91Cr	-2.06Cr -1.8Cr -1.66Cr -1.53Cr -2.89Cr -198.69Cr -2.95Cr -20Cr -7.82Cr -97Cr -7.75Cr -7.58Cr -334.99Cr
Net Debt	1.15Cr 1.01Cr 92.79L 85.53L 1.61Cr 110.81Cr 1.65Cr 11Cr 4.36Cr 54Cr 4.32Cr 4.23Cr 186.83Cr	91.41L 79.88L 73.71L 67.95L 1.28Cr 88Cr 1.31Cr 8.81Cr 3.47Cr 43Cr 3.43Cr 3.36Cr 148.42Cr

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

157

Sector

Market Closed - Deutsche Boerse AG Other stock markets 11:40:06 21/06/2024 am IST			5-day change	1st Jan Change
0.0100 ^EUR	-71.43%		-.--%	-

27/25/27	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/25/19	EnVVeno Medical Names Jennifer Bright CFO	MT

27/25/27	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/25/19	EnVVeno Medical Names Jennifer Bright CFO	MT
05/25/05	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/25/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/25/21	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/25/18	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/25/14	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/25/29	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/25/14	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/25/13	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/25/08	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/24/23	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/24/15	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/24/01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/23/31	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/23/20	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/22/20	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/25/14	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/24/08	Biolase: Q3 Earnings Snapshot	AQ
08/24/08	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
02/24/02	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
09/24/09	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Martha Somerman BRD	Director/Board Member	-	16/08/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	-71.43%	-.--%	-	-	36
CHURCHILL CAPITAL CORP XI	-0.96%	-6.95%	-	-	81Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.10%	-0.20%	-	-	64Cr
DEEP FISSION, INC.	+1.33%	-4.14%	-	-	64Cr
CHURCHILL CAPITAL CORP XII	+0.56%	+0.85%	-	-	61Cr
CANTOR EQUITY PARTNERS IV, INC.	-0.14%	-0.05%	-	-	60Cr
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	-0.44%	-	-	60Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-1.53%	-1.53%	-	-	57Cr
CENTIEL AG	-2.80%	+8.17%	+241.94%	-71.63%	56Cr
Average	-8.35%	-0.54%	+241.94%	-71.63%	62.9Cr
Weighted average by Cap.	-0.44%	-0.88%	+241.94%	-71.63%